Bellerophon_banner_home_v2_d3

Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.

We are focused on developing innovative therapies in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
More About Us

Bellerophon Therapeutics COVID-19 Statement

As news about COVID-19 continues to unfold, the safety and well-being of our employees, as well as the patients and the healthcare professionals we serve in and outside of hospital settings, is of the upmost importance to Bellerophon Therapeutics during these unprecedented times.

On March 20, 2020, the FDA granted emergency expanded access allowing our proprietary inhaled nitric oxide (iNO) delivery system, INOpulse®, to immediately be used for the treatment of COVID-19. Based on the genetic similarities between SARS-CoV and COVID-19, results from SARS-CoV clinical studies support the potential for iNO to provide meaningful benefit for patients infected with COVID-19. Treatment with the INOpulse system was initiated for the first time in a patient with a diagnosis of COVID-19 at the end of March 2020.

For more information on our Expanded Access program, please call 908-574-4770 or email EAP@Bellerophon.com.

The Bellerophon Therapeutics team will continue to work closely with the FDA to make INOpulse available to more patients around the U.S. under the Expanded Access program in our collective fight against the pandemic. More updates will be shared about our clinical development progress at a later date.

Voľte tak, aby ste si boli istí, že vám balenie vystačí, ale zároveň, že nebude príliš veľké a že spotrebujete čo najväčšiu časť tabliet. Skúste na tomto webe sa menej stresovať, viac hýbať, stravovať ľahšie a svoj organizmus nakopnete. Aj keď vám pomôže dočasne udržať erekciu, aby ste mohli mať sex, nevylieči ed.

Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About Inopulse

Bellerophon Therapeutics Inc. News Release

A Collection of Bellerophon Therapeutics Inc. News Release

Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock
04/01/2020 05:06 PM

WARREN, N.J. , April 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, closed its previously announced registered direct offering of 1,275,000 shares of its common stock at a purchase price of

Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19
03/31/2020 12:30 PM

WARREN, N.J. , March 31, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it will host an investor conference call and webcast on the INOpulse ® inhaled

Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market
03/30/2020 01:57 PM

WARREN, N.J. , March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the

Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
03/30/2020 12:00 PM

WARREN, N.J. , March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse® inhaled nitric oxide system

FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus
03/20/2020 12:30 PM

WARREN, N.J. , March 20, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted emergency expanded access allowing its proprietary

Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis
03/10/2020 12:30 PM

WARREN, N.J. , March 10, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the successful completion of its End-of-Phase 2 Meetings with the U.S.

Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis
02/18/2020 01:30 PM

WARREN, N.J. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study

Bellerophon Announces 1-for-15 Reverse Stock Split
02/07/2020 05:00 PM

WARREN, N.J. , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the filing of a certificate of amendment to its amended and restated certificate of incorporation with the

More News

Our goal is to become a leader in developing and commercializing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

More About Pipeline

 


Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About Inopulse

Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. 

 

More About Our Pipeline

More News

Samen met het helpen om energie te verhogen. Ruste ad fraza plaats kijkt terug op de laatste keer dat ik veilig viagra kopen noemde het gebruik van een natuurlijke.